טוען...
The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different do...
שמור ב:
| הוצא לאור ב: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6178936/ https://ncbi.nlm.nih.gov/pubmed/30323627 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S176429 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|